Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Baxter
Teva
Dow
UBS
Cipla
Queensland Health
Express Scripts
Chubb
Federal Trade Commission

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,428,810

« Back to Dashboard

Which drugs does patent 6,428,810 protect, and when does it expire?

Patent 6,428,810 protects PRILOSEC, PRILOSEC OTC, NEXIUM, and NEXIUM 24HR, and is included in seven NDAs.

Protection for NEXIUM has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-one patent family members in nineteen countries.
Summary for Patent: 6,428,810
Title: Pharmaceutical formulation comprising omeprazole
Abstract:An enteric coated oral pharmaceutical formulation comprising as active ingredient a compound selected from the group of omeprazole, an alkaline salt of omeprazole, one of the single enantiomers of omeprazole and an alkaline salt of one of the single enantiomers of omeprazole, wherein the formulation comprises a core material that comprises the active ingredient and optionally an alkaline reacting compound, the active ingredient is in admixture with a pharmaceutically acceptable excipient, such as for instance a binding agent, and on said core material a separating layer and an enteric coating layer. A hydroxypropyl cellulose (HPC) with a specific cloud point is used in the manufacture of the claimed pharmaceutical formulations. Furthermore, the application describes the processes for their preparation and the use of the claimed formulations in medicine.
Inventor(s): Bergstrand; Pontus (Gothenburg, SE), Wang; Peter (Molndal, SE)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:09/485,218
Patent Claim Types:
see list of patent claims
Formulation; Compound; Composition; Use; Process;

Drugs Protected by US Patent 6,428,810

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Covis Pharma Bv PRILOSEC omeprazole magnesium FOR SUSPENSION, DELAYED RELEASE;ORAL 022056-001 Mar 20, 2008 RX Yes No ➤ Sign Up ➤ Sign Up Y PEDIATRIC USE AGES 1 MONTH TO 2 YEARS, GERD AND EROSIVE ESOPHAGITIS ➤ Sign Up
Covis Pharma Bv PRILOSEC omeprazole magnesium FOR SUSPENSION, DELAYED RELEASE;ORAL 022056-001 Mar 20, 2008 RX Yes No ➤ Sign Up ➤ Sign Up Y PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS ➤ Sign Up
Covis Pharma Bv PRILOSEC omeprazole magnesium FOR SUSPENSION, DELAYED RELEASE;ORAL 022056-002 Mar 20, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS ➤ Sign Up
Astrazeneca Pharms PRILOSEC OTC omeprazole magnesium TABLET, DELAYED RELEASE;ORAL 021229-001 Jun 20, 2003 OTC Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Astrazeneca Pharms NEXIUM esomeprazole magnesium CAPSULE, DELAYED REL PELLETS;ORAL 021153-001 Feb 20, 2001 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca Pharms NEXIUM esomeprazole magnesium CAPSULE, DELAYED REL PELLETS;ORAL 021153-002 Feb 20, 2001 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca Lp NEXIUM 24HR esomeprazole magnesium CAPSULE, DELAYED RELEASE;ORAL 204655-001 Mar 28, 2014 OTC Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca Pharms NEXIUM esomeprazole magnesium FOR SUSPENSION, DELAYED RELEASE;ORAL 021957-003 Dec 15, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca Pharms NEXIUM esomeprazole magnesium FOR SUSPENSION, DELAYED RELEASE;ORAL 021957-004 Dec 15, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca Pharms NEXIUM esomeprazole magnesium FOR SUSPENSION, DELAYED RELEASE;ORAL 022101-001 Feb 27, 2008 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,428,810

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9803772Nov 05, 1998
PCT Information
PCT FiledNovember 03, 1999PCT Application Number:PCT/SE99/01989
PCT Publication Date:May 18, 2000PCT Publication Number: WO00/27366

International Patents Family Members for US Patent 6,428,810

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 774278 ➤ Sign Up
Brazil 9915087 ➤ Sign Up
Canada 2346988 ➤ Sign Up
European Patent Office 1124539 ➤ Sign Up
China 1325300 ➤ Sign Up
China 1160062 ➤ Sign Up
Germany 69909316 ➤ Sign Up
Denmark 1124539 ➤ Sign Up
Spain 2201837 ➤ Sign Up
Hong Kong 1039070 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Federal Trade Commission
Mallinckrodt
Medtronic
Chubb
Teva
UBS
Chinese Patent Office
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot